MetaCap

Collegium Pharmaceutical (COLL) vs Oric Pharmaceuticals (ORIC)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Oric Pharmaceuticals (ORIC) has outperformed Collegium Pharmaceutical (COLL) over the past year, losing 36.7% versus a loss of 45.2%. Over five years, COLL leads with a +37.7% price change compared with -48.6% for ORIC. Collegium Pharmaceutical is the larger company by market cap ($768.2 million vs $764.9 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

COLL-45.24%ORIC-36.66%
+30%-13%-56%
Nov 21, 20251 yearNov 20, 2026
COLL+31.14%ORIC-55.39%
+177%+40%-98%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

COLL versus ORIC key metrics
MetricCOLLORIC
Share price$24.72$7.36
Market cap$768.18M$764.94M
1-day change-1.94%-4.42%
YTD return-46.61%-10.02%
1-year return-45.24%-36.66%
5-year return+37.72%-48.64%
P/E ratio (TTM)22.68—
Forward P/E3.49—
EPS (TTM)$1.09$-1.44
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$780.57M—
Revenue growth (YoY)+23.62%—
Net income (latest FY)$62.87M$-129.47M
Gross margin59.35%—
Operating margin23.01%—
Net margin8.05%—
52-week high$50.79$14.68
52-week low$21.43$7.23
Distance from 52-week high-51.33%-49.86%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+77.99%+194.97%
Average volume754.45K1.59M
Shares outstanding31.08M103.93M
Employees423111
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Collegium Pharmaceutical

COLL stock →

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.

Health Care · Biotechnology: Pharmaceutical Preparations · 423 employees

About Oric Pharmaceuticals

ORIC stock →

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study.

Health Care · Biotechnology: Pharmaceutical Preparations · 111 employees

COLL vs ORIC FAQ

Which is bigger, Collegium Pharmaceutical or Oric Pharmaceuticals?

Collegium Pharmaceutical (COLL) is larger, with a market capitalization of $768.18M compared with $764.94M for Oric Pharmaceuticals (ORIC).

Which stock has performed better over the past year, COLL or ORIC?

ORIC returned -36.66% over the past 12 months, compared with -45.24% for COLL (price return, excluding dividends). Past performance does not predict future results.

Are Collegium Pharmaceutical and Oric Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons